Operator
Good afternoon, ladies and gentlemen. And welcome to the Flexion Therapeutics First Quarter 2021 Financial Results Conference Call. [Operator Instructions] We will be facilitating a question-and-answer session at the end of today s call. [Operator Instructions]
I ll now turn the call over to Scott Young, Flexion s Vice President of Corporate Communications and Investor Relations.
Scott Young
Vice President of Corporate Communications & Investor Relations
Good afternoon. A short while ago, we issued a press release announcing our Q1 2021 financial results. In addition, today, we are introducing refreshed metrics to provide increased visibility and insights into the commercial performance of ZILRETTA. Our earnings press release and the commercial metrics slide can be found under the Investors tab on the company s website and a replay of this call will be accessible there shortly after its conclusion.
Tejon Ranch Co. Names Senior Vice President of Real Estate
May 10, 2021 18:00 ET | Source: Tejon Ranch Co Tejon Ranch Co LEBEC, California, UNITED STATES
TEJON RANCH, Calif., May 10, 2021 (GLOBE NEWSWIRE) Tejon Ranch Co. (NYSE: TRC) announced today that Rachel Freeman has joined the company as Senior Vice President of Real Estate. Freeman is a veteran real estate executive with 15 years of experience. She has successfully led the entitlement strategies for a diverse array of commercial real estate assets, traversing the multifaceted regulatory, community, and political terrain of the Southern California landscape.
“We are extremely pleased to have a person of the caliber and experience of Rachel Freeman join our team,” said Gregory S. Bielli, President and CEO of Tejon Ranch Co. “She has a track record of success and her experience and knowledge of real estate development in Southern California will serve us well.”
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop
th C1-Inhibitor Deficiency Angioedema Workshop, which will be held virtually from June 3-6, 2021.
The presentation details are as follows:
Title: Fast improvement of hereditary angioedema (HAE) attacks with the oral on-demand plasma kallikrein inhibitor KVD900: an analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity during a double-blind, randomized phase 2 cross-over trial in patients with HAE type I and II
Session Date and Time: Saturday, June 5, 2021, 9:45 a.m. CEST
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Tejon Ranch Co. Names Senior Vice President of Real Estate
Tejon Ranch CoMay 10, 2021 GMT
TEJON RANCH, Calif., May 10, 2021 (GLOBE NEWSWIRE) Tejon Ranch Co. (NYSE: TRC) announced today that Rachel Freeman has joined the company as Senior Vice President of Real Estate. Freeman is a veteran real estate executive with 15 years of experience. She has successfully led the entitlement strategies for a diverse array of commercial real estate assets, traversing the multifaceted regulatory, community, and political terrain of the Southern California landscape.
“We are extremely pleased to have a person of the caliber and experience of Rachel Freeman join our team,” said Gregory S. Bielli, President and CEO of Tejon Ranch Co. “She has a track record of success and her experience and knowledge of real estate development in Southern California will serve us well.”
Athersys Reports First Quarter 2021 Results
Search jobs
Management to host conference call at 4:30 pm EDT today
CLEVELAND (BUSINESS WIRE) $ATHX#Athersys Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2021 and provided a corporate update.
“Since our recent call, we remain on track with respect to our operating plans,” stated Mr. William (B.J.) Lehmann, Jr., Interim Chief Executive Officer of Athersys. “We look forward to important progress during the remaining course of the year, including expected top-line results from the TREASURE and ONE-BRIDGE studies in Japan.”
“Additionally, we remain focused on important priorities for the year, which include advancing our MASTERS-2 study and other clinical programs, supporting our partner, Healios, as it prepares for important regulatory applications, and in further developing our commercial manufacturing processes and planning,” added Mr. Lehmann.